Join this virtual case-based CME activity that explores IDH and FLT3 mutations and how they influence prognosis and guide targeted therapy decisions in patients with AML. Our expert faculty will discuss clinical data supporting IDH1/2 inhibitors and FLT3-targeted agents and review treatment sequencing, resistance patterns, and integration of novel therapies into practice. The conversation will also take a deep dive into precision medicine and evidence-based care strategies to treat patients with AML who have these actionable mutations.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
97% of listed courses are free
34 of 35 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Communication & Shared Decision-Making
- Dermatology
- Gastroenterology
- General Pediatrics
- Hematology
- Medical Oncology
- Nephrology
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Psychotic Disorders
- Rheumatology
- Surgical Oncology
- Cross-Specialty
- GI & Liver
- Medical Subspecialties
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pathology & Lab
- Pediatrics
- Psychiatry
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Case-based learning
- Credit · Up to 1.5 credits
- Commercial Support
-
ReleasedDec 18, 2025
-
Last day to claim creditDec 19, 2026 2 months left
-
Plexus Communications +1 Navigating the Frontier of First-Line Treatments for FLT3-Mutated Acute Myeloid Leukemia
-
Efficient CME, CME Outfitters, LLC Navigating Common Pitfalls in Acute Myeloid Leukemia: Expert Strategies for the Recognition and Management of FLT3-Mutated Disease
-
Physicians’ Education Resource Medical Crossfire : Experts Debate the Hottest Topics in AML FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies
-
Paradigm Medical Communications, LLC Expert Insights on Managing IDH- and FLT3-Mutant AML: Bringing Precision Medicine to Daily Practice
-
Paradigm Medical Communications, LLC Quiz and Learn: How Well Do You Know Treatment Options for CLL?
-
Paradigm Medical Communications, LLC The Many Faces of Neovascular Retinal Disease: Individualizing the Use of Sustained Delivery Therapy
